Taken together, these results indicate that a combinatorial treatment approach that targets at least one relevant melanoma survival pathway (MEK–ERK) and the TRAIL signaling pathway has significant anti-tumor activity in vivo even against a tumor poorly responsive to a MEK inhibitor and completely resistant to TRAIL. The gene discussed is TNFSF10; the disease is melanoma.